Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
Authors:
- Eva FernlundEFEva Fernlund
- Martin ErikssonMEMartin Eriksson
- Jonas SöderholmJSJonas Söderholm
- Jan SunnegårdhJSJan Sunnegårdh
- Estelle NaumburgENEstelle Naumburg
Open Access
- 1 October 2020
- journal article
- research article
- Published by Springer Nature in Journal of Congenital Cardiology
- Vol. 4 (1)
Abstract
Background: Infants with congenital heart disease (CHD) have an increased risk of morbidity and mortality during a respiratory syncytial virus (RSV) infection. The aim of this study was to estimate the cost-effectiveness of palivizumab as RSV-prophylaxis among infants with CHD, including the effect of delayed heart surgery and asthma.Methods: A simulation model with data from the literature and health care authorities including costs and utilities was developed to estimate costs and health effects over a lifetime for a cohort of CHD infants receiving palivizumab compared to no RSV-prophylaxis.Results: The prophylaxis treatment incurred a cost of 3664 EUR per treated infant. However, due to cost-savings from primarily avoiding hospitalizations (5145 EUR/treated infant) and avoiding heart complications due to delayed heart surgery (2082 EUR/treated infant), the RSV-prophylaxis treatment resulted in a total cost-saving of 3833 EUR per treated infant. At the same time, the prophylaxis-treated cohort accumulated more life-years and higher quality of life than the non-prophylaxis cohort.Conclusion: This study confirms that RSV-prophylaxis in severe CHD infants less than one year of age is cost beneficial. Avoiding delayed heart surgeries is an important benefit of prophylaxis and should be taken into consideration.Keywords
This publication has 41 references indexed in Scilit:
- A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United KingdomHealth Economics Review, 2013
- Managing the Morbidity Associated with Respiratory Viral Infections in Children with Congenital Heart DiseaseInternational Journal of Pediatrics, 2012
- Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From AustriaThe Pediatric Infectious Disease Journal, 2012
- Economic Evaluation of Palivizumab in Children With Congenital Heart Disease: A Canadian PerspectiveCanadian Journal of Cardiology, 2011
- Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of lifeThorax, 2010
- Cost effectiveness of palivizumab in Spain: an analysis using observational dataThe European Journal of Health Economics, 2009
- Wheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High-Risk ChildrenAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Epidemiologic, Experimental, and Clinical Links between Respiratory Syncytial Virus Infection and AsthmaClinical Microbiology Reviews, 2008
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: a collaborative report.Archives of Disease in Childhood - Fetal and Neonatal Edition, 1995